We attempt to elucidate the performance of serum prostate specific antigen (PSA) as a screening test for prostate cancer.
We analyzed sera stored since 1980 in a nested case-control study.
The 36 patients with prostate cancer had a markedly greater mean serum PSA level than did 68 subjects without cancer (22.71 versus 2.67, respectively, p<0.0001).
Among the controls 24% had a serum PSA of greater than 4.0 mug./l. A serum PSA value exceeding 4.0 mug./l. in 1980 was associated with a 20-fold excess risk of cancer between 1981 and 1986, and an 8-fold risk between 1987 and 1991.
Diagnosis of clinically significant prostate cancer can be advanced substantially by serum PSA testing.
However, the large number of high serum PSA values in men who remained free of clinical disease emphasizes the need for a more specific screening test.
Mots-clés Pascal : Epithélioma, Prostate, Marqueur tumoral, Antigène associé tumeur, Exploration, Dépistage, Epidémiologie, Vieillard, Homme, Mâle, Suède, Europe, Appareil génital mâle pathologie, Prostate pathologie, Appareil urinaire pathologie, Tumeur maligne, Antigène PSA
Mots-clés Pascal anglais : Carcinoma, Prostate, Tumoral marker, Tumor associated antigen, Exploration, Medical screening, Epidemiology, Elderly, Human, Male, Sweden, Europe, Male genital diseases, Prostate disease, Urinary system disease, Malignant tumor, Prostate specific antigen
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0530037
Code Inist : 002B14D02. Création : 01/03/1996.